Valuation: Enovis Corporation

Capitalization 1.37B 1.17B 1.07B 1.01B 1.87B 128B 1.91B 12.55B 4.94B 61.34B 5.12B 5.02B 218B P/E ratio 2026 *
84.8x
P/E ratio 2027 * 28.2x
Enterprise value 2.57B 2.19B 2.01B 1.9B 3.51B 241B 3.59B 23.62B 9.3B 115B 9.64B 9.44B 410B EV / Sales 2026 *
1.1x
EV / Sales 2027 * 0.98x
Free-Float
97.34%
Yield 2026 *
-
Yield 2027 * -
1 day+0.13%
1 week-6.20%
Current month+4.44%
1 month+5.55%
3 months+0.89%
6 months-27.43%
Current year-10.81%
1 week 23.38
Extreme 23.38
27.04
1 month 21.48
Extreme 21.48
27.04
Current year 21
Extreme 21
29.89
1 year 21
Extreme 21
37.85
3 years 21
Extreme 21
66.14
5 years 21
Extreme 21
164.01
10 years 21
Extreme 21
164.01
Manager TitleAgeSince
Chief Executive Officer 61 11/05/2025
Director of Finance/CFO 47 31/12/2022
Chief Administrative Officer - 04/01/2026
Director TitleAgeSince
Director/Board Member 55 12/05/2008
Director/Board Member 67 20/09/2010
Chairman 64 20/05/2025
Change 5d. change 1-year change 3-years change Capi.($)
+0.13%-6.20%-27.16%-59.20% 1.37B
+0.63%-3.48%-5.39%+9.04% 125B
-0.53%-3.84%+23.47%-4.93% 14.08B
-0.38%+0.54%+35.57%+152.70% 7.14B
+0.39%-1.54%-35.70%-69.80% 5.05B
+1.23%-0.22%+26.95%+10.98% 2.62B
+1.12%+8.88%-9.63%-16.51% 2.05B
+0.23%-1.09%+15.09%-19.20% 1.77B
+4.17%-4.31%-63.55%-80.33% 1.5B
Average +0.76%-0.35%-4.48%-8.58% 17.88B
Weighted average by Cap. +0.50%-4.37%-2.03%+9.71%

Financials

2026 *2027 *
Net sales 2.34B 2B 1.83B 1.73B 3.2B 220B 3.27B 21.52B 8.48B 105B 8.78B 8.6B 373B 2.47B 2.11B 1.93B 1.83B 3.37B 231B 3.45B 22.68B 8.93B 111B 9.26B 9.06B 393B
Net income -28.92M -24.68M -22.64M -21.41M -39.51M -2.71B -40.39M -266M -105M -1.3B -108M -106M -4.61B 45.76M 39.05M 35.82M 33.88M 62.51M 4.29B 63.9M 421M 166M 2.06B 172M 168M 7.29B
Net Debt 1.2B 1.03B 943M 892M 1.65B 113B 1.68B 11.07B 4.36B 54.1B 4.52B 4.42B 192B 1.05B 896M 822M 778M 1.44B 98.53B 1.47B 9.66B 3.8B 47.19B 3.94B 3.86B 167B
Logo Enovis Corporation
Enovis Corporation is a medical technology company. It is focused on developing clinically differentiated solutions by manufacturing and distributing medical devices with a range of products used for reconstructive surgery, rehabilitation, pain management and physical therapy. It operates through two segments: Prevention & Recovery and Reconstructive. The Prevention & Recovery segment develops, manufactures, and distributes rigid bracing products, orthopedic soft goods, vascular systems and compression garments, and hot and cold therapy products and offers recovery sciences products in the clinical rehabilitation and sports medicine markets, such as bone growth stimulators and electrical stimulators used for pain management. The Reconstructive segment develops, manufactures, and markets a variety of knee, hip, shoulder, elbow, foot, ankle, and finger implant products and surgical productivity tools. It also provides Novastep, a minimally invasive surgery (MIS) foot and ankle solutions.
Employees
7,802
Date Price Change Volume
22/04/26 23.76 $ +0.13% 906,028
21/04/26 23.73 $ -9.67% 1,376,140
20/04/26 26.27 $ -0.19% 525,539
17/04/26 26.32 $ +4.44% 1,755,176
16/04/26 25.20 $ -0.51% 757,154
Trader
Investor
Global
Quality
ESG MSCI
A
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
12
Last Close Price
23.73USD
Average target price
44.73USD
Spread / Average Target
+88.48%

Quarterly revenue - Rate of surprise